Cargando…
SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
OBJECTIVES: As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. METHODS: This study exa...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442529/ https://www.ncbi.nlm.nih.gov/pubmed/34536610 http://dx.doi.org/10.1016/j.ijid.2021.09.021 |
_version_ | 1783753026335408128 |
---|---|
author | Vacharathit, Vimvara Srichatrapimuk, Sirawat Manopwisedjaroen, Suwimon Kirdlarp, Suppachok Srisaowakarn, Chanya Setthaudom, Chavachol Inrueangsri, Nanthicha Pisitkun, Prapaporn Kunakorn, Mongkol Hongeng, Suradej Sungkanuparph, Somnuek Thitithanyanont, Arunee |
author_facet | Vacharathit, Vimvara Srichatrapimuk, Sirawat Manopwisedjaroen, Suwimon Kirdlarp, Suppachok Srisaowakarn, Chanya Setthaudom, Chavachol Inrueangsri, Nanthicha Pisitkun, Prapaporn Kunakorn, Mongkol Hongeng, Suradej Sungkanuparph, Somnuek Thitithanyanont, Arunee |
author_sort | Vacharathit, Vimvara |
collection | PubMed |
description | OBJECTIVES: As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. METHODS: This study examined the longitudinal profiles of neutralizing antibody (NAb) titers in hospitalized COVID-19 patients clinically diagnosed with mild symptoms, pneumonia, or severe pneumonia, up to 12 months after illness onset, using live-virus neutralization. Multiplex, correlation, and network analyses were used to characterize serum-derived inflammatory cytokine profiles in all severity groups. RESULTS: Peak NAb titers correlated with disease severity, and NAb titers declined over the course of 12 months regardless of severity. Multiplex analyses revealed that IP-10, IL-6, IL-7, and VEGF-α were significantly elevated in severe pneumonia cases compared to those with mild symptoms and pneumonia cases. Correlation and network analyses further suggested that cytokine network formation was distinct in different COVID-19 severity groups. CONCLUSIONS: The study findings inform on the long-term kinetics of naturally acquired serological immunity against SARS-CoV-2 and highlight the importance of identifying key cytokine networks for potential therapeutic immunomodulation. |
format | Online Article Text |
id | pubmed-8442529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84425292021-09-15 SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile Vacharathit, Vimvara Srichatrapimuk, Sirawat Manopwisedjaroen, Suwimon Kirdlarp, Suppachok Srisaowakarn, Chanya Setthaudom, Chavachol Inrueangsri, Nanthicha Pisitkun, Prapaporn Kunakorn, Mongkol Hongeng, Suradej Sungkanuparph, Somnuek Thitithanyanont, Arunee Int J Infect Dis Article OBJECTIVES: As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. METHODS: This study examined the longitudinal profiles of neutralizing antibody (NAb) titers in hospitalized COVID-19 patients clinically diagnosed with mild symptoms, pneumonia, or severe pneumonia, up to 12 months after illness onset, using live-virus neutralization. Multiplex, correlation, and network analyses were used to characterize serum-derived inflammatory cytokine profiles in all severity groups. RESULTS: Peak NAb titers correlated with disease severity, and NAb titers declined over the course of 12 months regardless of severity. Multiplex analyses revealed that IP-10, IL-6, IL-7, and VEGF-α were significantly elevated in severe pneumonia cases compared to those with mild symptoms and pneumonia cases. Correlation and network analyses further suggested that cytokine network formation was distinct in different COVID-19 severity groups. CONCLUSIONS: The study findings inform on the long-term kinetics of naturally acquired serological immunity against SARS-CoV-2 and highlight the importance of identifying key cytokine networks for potential therapeutic immunomodulation. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-11 2021-09-15 /pmc/articles/PMC8442529/ /pubmed/34536610 http://dx.doi.org/10.1016/j.ijid.2021.09.021 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Vacharathit, Vimvara Srichatrapimuk, Sirawat Manopwisedjaroen, Suwimon Kirdlarp, Suppachok Srisaowakarn, Chanya Setthaudom, Chavachol Inrueangsri, Nanthicha Pisitkun, Prapaporn Kunakorn, Mongkol Hongeng, Suradej Sungkanuparph, Somnuek Thitithanyanont, Arunee SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile |
title | SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile |
title_full | SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile |
title_fullStr | SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile |
title_full_unstemmed | SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile |
title_short | SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile |
title_sort | sars‐cov‐2 neutralizing antibodies decline over one year and patients with severe covid‐19 pneumonia display a unique cytokine profile |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442529/ https://www.ncbi.nlm.nih.gov/pubmed/34536610 http://dx.doi.org/10.1016/j.ijid.2021.09.021 |
work_keys_str_mv | AT vacharathitvimvara sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT srichatrapimuksirawat sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT manopwisedjaroensuwimon sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT kirdlarpsuppachok sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT srisaowakarnchanya sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT setthaudomchavachol sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT inrueangsrinanthicha sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT pisitkunprapaporn sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT kunakornmongkol sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT hongengsuradej sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT sungkanuparphsomnuek sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT thitithanyanontarunee sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile |